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Abstract
Background: Local reactions are the most commonly reported adverse events following tetanus
and diphtheria toxoid (Td) vaccine and the risk of local reactions may increase with number of prior
Td vaccinations.
Methods: To estimate the risk of medically attended local reactions following Td vaccination in
adolescents and young adults we conducted a six-year retrospective cohort study assessing
436,828 Td vaccinations given to persons 9 through 25 years of age in the Vaccine Safety Datalink
population from 1999 through 2004.
Results: Overall, the estimated risk of a medically attended local reaction was 3.6 events per
10,000 Td vaccinations. The lowest risk (2.8 events per 10,000 vaccinations) was found in the 11
to 15 year old age group. In comparison with that group, the event risks were significantly higher
in both the 9 to 10 and 21 to 25 year old age groups. The risk of a local reaction was significantly
higher in persons who had received another tetanus and diphtheria toxoid containing vaccine
(TDCV) in the previous five years (incidence rate ratio, 2.9; 95% confidence interval, 1.2 to 7.2).
Twenty-eight percent of persons with a local reaction to Td vaccine were prescribed antibiotics.
Conclusion: Medically attended local reactions were uncommon following Td vaccination. The
risk of those reactions varied by age and by prior receipt of TDCVs. These findings provide a point
of reference for future evaluations of the safety profile of newer vaccines containing tetanus or
diphtheria toxoid.
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Background
Local reactions are the most commonly reported adverse
events following administration of tetanus and diphtheria
toxoid containing vaccines (TDCVs), and the risk of local
reactions may increase with the number of prior vaccina-
tions [1]. Local reactions, and particularly reactions that
result in a medical visit, are therefore an outcome of inter-
est in postlicensure assessments of the safety of TDCVs.
Three vaccines containing tetanus or diphtheria toxoid are
currently licensed for routine use in adolescents and
young adults in the United States. Of those, tetanus and
diphtheria toxoid and acellular pertussis (Tdap) vaccine
and quadrivalent meningococcal conjugate vaccine (Men-
actra) (which contains meningococcal polysaccharide
covalently linked to a diphtheria toxoid protein carrier),
were introduced in 2005 and are now part of the routine
adolescent immunization schedule. The older tetanus and
diphtheria toxoid (Td) vaccine has been used for over 40
years.
Interpretation of the findings of postlicensure safety
assessments of Tdap and Menactra vaccines would be
aided by knowledge of the expected risk of medically
attended local reactions following Td vaccine. To estimate
the risk of medically attended local reactions following Td
vaccination in adolescents and young adults we con-
ducted a six-year retrospective cohort study assessing
436,828 Td vaccinations given to members of the Vaccine
Safety Datalink (VSD) population in the era prior to the
introduction of Tdap and Menactra vaccines.
Methods
The study population included members of seven man-
aged care organizations (MCOs) participating in the VSD
project, a collaborative project between the CDC and
eight MCOs established in 1991 to monitor and evaluate
vaccine safety [2,3]. This project collects data on more
than 8.8 million members annually including informa-
tion on demographics, health plan enrollment, vaccina-
tions, and medical encounters. The study cohort included
MCO members who had a Td vaccination recorded at the
MCO when they were 9 through 25 years of age and from
January 1, 1999 through December 15, 2004. Participat-
ing MCOs included Group Health, Northern California
Kaiser Permanente, Kaiser Permanente Northwest, Kaiser
Permanente Colorado, Harvard Pilgrim Healthcare and
Harvard Vanguard Medical Associates, Marshfield Clinic,
and HealthPartners. At the time of this study, the first
three of the listed MCOs were funded through the VSD to
conduct assessments in children and adults and the
remaining sites were funded only for child assessments.
Therefore, for this study, all seven sites contributed infor-
mation on vaccines given to persons 9 through 17 years of
age, and three sites also contributed information on vac-
cines given to persons 18 through 25 years of age. Vacci-
nations were identified from computerized
immunization records maintained by each MCO.
The primary study outcome was a chart-confirmed medi-
cally-attended local reaction, and a secondary outcome
was a chart-confirmed medically-attended illness possibly
indicative of a hypersensitivity response. An important
distinction between these outcomes is that while local
reactions are relatively easily attributable to a preceding
vaccination, signs and symptoms such as hives or rash
that are consistent with a hypersensitivity response are
non-specific and in many cases may be attributable to
exposures or etiologies other than vaccination.
Outcome events were presumptively identified by selected
International Classification of Diseases 9th Revision Clinical
Modification (ICD9-CM) codes assigned to inpatient and
outpatient medical encounters within six days following
the Td vaccination date (Table 1). The ICD9-CM codes
used to identify presumptive events were selected based
on expert opinion and information from previous studies.
Since diagnosis codes assigned on the day of vaccination
(day 0) often represent pre-existing conditions, and since
most adverse events following vaccination are not
expected to result in a medical visit on the same calendar
day as vaccination, presumptive cases were not defined by
a diagnosis code of cellulitis, limb swelling, pain in limb,
allergy unspecified, lymphadenitis, or urticaria assigned
on the day of vaccination. Presumptive cases defined by
one of the above listed codes who had also had that code
assigned within the 30 days prior to vaccination were also
excluded. Since immediate hypersensitivity events could
lead to a medical visit on the day of vaccination, diagnosis
codes most consistent with an immediate hypersensitivity
reaction, or which were specific indicators of adverse
events, assigned on days 0 through 6 were used to pre-
sumptively identify events.
Presumptive cases defined by the above criteria were then
validated by medical record review to confirm the occur-
rence of a medically-attended local reaction or an illness
possibly indicative of a hypersensitivity response to Td
vaccine and to collect additional information on the char-
acteristics of those events. A validated medically-attended
local reaction was defined by reported signs or symptoms
consistent with a local reaction (inflammation, ulcera-
tion, erythema, warmth, swelling, pain, or tenderness)
that were not known to have onset prior to vaccination
and were not clearly due to another known cause (for
example, trauma or insect sting). A validated illness possi-
bly indicative of a hypersensitivity reaction was defined by
a report of signs or symptoms consistent with urticaria,
hives, wheezing, respiratory collapse, hypotension,
angioedema, or anaphylaxis that were not known to have
onset prior to vaccination. For validated illnesses possiblyBMC Infectious Diseases 2009, 9:165 http://www.biomedcentral.com/1471-2334/9/165
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indicative of a hypersensitivity reaction, medical record
review was also conducted to determine whether the event
could be confirmed to have met the Brighton Collabora-
tion case definition of anaphylaxis [4].
We identified 1,097 presumptive events following
436,828 Td vaccinations. Due to resource constrains, the
maximum number of presumptive events selected for
chart review at each of the participating MCOs was limited
to 200. Two sites had more than 200 presumptive events
identified and so for those sites a random sample of 200
presumptive events was selected for confirmatory review.
The total number of presumptive events identified for
confirmatory review across all sites was 765. Of those,
chart review could not be completed for 52 events because
the medical record lacked information on the post-vacci-
nation encounter and so chart review was completed for
713 presumptive events.
The study was approved by the Group Health Institutional
Review Board and, as appropriate, by institutional review
boards at each of the participating sites.
Statistical methods
Since about a third of the presumptive events were not
reviewed, calculation of outcome rates based only on
chart review verified events would underestimate the true
event rate. To obtain statistically valid estimates of the true
event rates that account for those missing data we used
multiple imputation, based on Rubin's method [5]. This
involved three basic steps. First, we imputed values for the
outcome status of the presumptive events that were not
reviewed. That is, the presumptive events that were not
reviewed were assigned an imputed value of "validated"
or "not validated". The likelihood of assignment of a val-
idated status was based on the site-specific validation rate
of the presumptive events that were reviewed. That is, if
50% of presumptive events at a given site that were
reviewed were validated, then there was a 50% likelihood
that each presumptive event not reviewed at that site
would be assigned an imputed value of validated. We then
"filled in the blanks" by using those site-specific likeli-
hoods to assign each of the presumptive events that were
not reviewed a validation status. This step was repeated
four more times, to create five datasets with completed
outcome validated status, either as determined by chart
review or as assigned by the imputation method.
Second, we conducted analyses of each of those five data-
sets. Specifically, for each dataset, we calculated the risk of
each validated event per 10,000 vaccinations and used
Poisson regression to estimate the rate ratio comparing
validated outcome risks between age and other subgroups
of interest. Last, we obtained final estimates and confi-
dence intervals based on the results of the five analyses
using multiple imputation averaging techniques that
account for the uncertainty introduced by the imputed
data.
To estimate the contribution of individual diagnosis
codes to the validated outcomes, we calculated the pro-
portion of validated events that were assigned each of the
codes and the proportion of presumptive events assigned
each of the codes that were validated. The latter analysis
was restricted to the presumptive events that were
reviewed.
Results
A total of 436,828 Td vaccinations administered to
430,568 persons meeting the study eligibility criteria were
identified (Table 2). Following the 436,828 Td vaccina-
tions, 1,097 presumptive medically attended events were
identified, 765 of those presumptive events were selected
for chart review, and reviews were completed for 713. Of
Table 1: Algorithm to define presumptive events by International Classification of Diseases 9th Revision Clinical Modification (ICD9-CM) 
codes associated with medical encounters within six days following vaccination.
ICD9-CM code(s) Description Presumptive events defined by a diagnosis code 
assigned on the day of vaccination (day 0) 
through day 6 or by a diagnosis code assigned 
on day 1 through day 6
682.3, 682.8, 682.9 Cellulitis Day 1 through day 6
729.81 Limb swelling Day 1 through day 6
729.5 Pain in limb Day 1 through day 6
995.3 Allergy unspecified Day 1 through day 6
708.x Urticaria Day 1 through day 6
289.3, 683, 785.6 Lymphadenitis Day 1 through day 6
999.3 Infection following infusion or vaccination Day 0 through day 6
995.0, 999.4 Anaphylaxis Day 0 through day 6
999.5 Serum reaction Day 0 through day 6
999.9 Complication of medical care Day 0 through day 6
995.2 Adverse effect of a drug or biological substance Day 0 through day 6BMC Infectious Diseases 2009, 9:165 http://www.biomedcentral.com/1471-2334/9/165
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the 713 presumptive events with completed reviews, 103
events met the definition of a medically attended local
reaction to Td vaccine and another 26 met the definition
of a validated illness possibly indicative of a hypersensi-
tivity reaction. Using multiple imputation, we further esti-
mated that among the 384 presumptive events not chart
reviewed (and therefore with a missing validated outcome
status) there were an additional 56 local reactions and 35
possible hypersensitivity reactions. This yielded a total of
159 estimated medically-attended local reactions and 61
illnesses possibly indicative of a hypersensitivity response
in the final analyses.
Medically attended local reactions
Risk of medically attended local reactions by age group and sex
The estimated risk of medically attended local reactions
was 3.6 events per 10,000 Td vaccinations administered
(Table 2). The lowest risk (2.8 events per 10,000 vaccina-
tions) was found in the 11 to 15 year old age group. In
comparison with that group, the event risks were signifi-
cantly higher in both the 9 to 10 and 21 to 25 year old age
groups. Compared to the 16 to 20 year old age group, the
risk among 21 to 25 year-olds was also significantly
higher. The risk of a medically attended local reaction did
not vary significantly by sex [3.9 events per 10,000 Td vac-
cinations for females and 3.4 events per 10,000 Td vacci-
nations for males (p = 0.4)].
Association of prior vaccination with risk of medically attended local 
reactions
The risk of a medically attended local reaction to Td vac-
cine was compared between persons who did and who
did not have a record of receipt of a TDCV within the pre-
vious five years. Prior vaccinations classified as TDCVs
included Td as well as diphtheria, tetanus and pertussis
vaccines administered as part of the childhood vaccina-
tion series but did not include Tdap or Menactra vaccines
as those vaccines were not available during the time
period of interest. In order to ensure accurate assessment
of prior vaccinations from the MCO records, the analyses
of TDCVs given before the Td vaccination were restricted
to persons with at least five years of continuous enroll-
ment in the MCO prior to the Td vaccination of interest.
Overall and in the younger age groups there was a trend
toward a higher risk of a local reaction in persons who
received Td within five years of a prior TDCV but only the
difference in all age groups combined was statistically sig-
nificant (Table 3).
Characteristics of validated medically attended local reactions as 
defined by medical record review
Of the 103 chart review validated local reactions, 97 were
reported to be associated with local edema, erythema, or
swelling and for 59 of those the size of the involved area
was noted. Of those, the distribution of the maximum
reported diameter of the local reaction was <10 cm for
83%, 10 to <15 cm for 10%, and ≥ 15 cm for 7%. Of the
four reactions reported to have a maximum diameter of ≥
15 cm, three were reported to involve the entire upper arm
and one of those extended to or past the elbow.
Of the 103 validated local reactions, 39 were noted to
have been associated with pain, two were associated with
ulcerated skin lesions, and 11 with lymphadenopathy.
Fever was uncommon; only five persons were docu-
mented to have a temperature of 100°F or higher at the
medical evaluation. No persons were evaluated in the
hospital, 25 were evaluated in the ED or urgent care, and
the remaining 78 were evaluated in outpatient clinics.
Twenty-three persons were given a clinical diagnosis of
cellulitis. Of those, four persons were treated with
parenteral antibiotics and 16 with oral antibiotics. Of the
80 persons with confirmed local reactions who were not
assigned a diagnosis of cellulitis, two were treated with
parenteral antibiotics and seven with oral antibiotics.
Diagnosis codes assigned to validated local reactions
The most common codes assigned to validated local reac-
tion events included codes for cellulitis, serum reaction,
complication of medical care, and adverse effect of a drug
or biological substance (Additional file 1). Together these
Table 2: Estimated risk of a validated medically attended local reaction by age at Td vaccination.
Age group, years Number Td vaccinations Estimated1 number of medically 
attended local reactions
Estimated event risk (95% CI) per 
10,000 Td vaccinations2
9-10 21,188 13 6.3 (3.4, 11.5)
11-15 310,803 88 2.8 (2.1, 3.7)
16-20 65,971 24 3.6 (2.3, 5.6)
21-25 38,866 34 8.7 (4.9, 15.7)
All 436,828 159 3.6 (2.8, 4.7)
CI = confidence interval
1The number of events estimated based on multiple imputation applied to account for incomplete chart reviews.
2Compared with the 11-15 year old age group, the risk was significantly higher in the 9-10 year old age group (p = 0.01) and the 21-25 year old age 
group (p = 0.005). The risk among 21-25 year olds was also significantly higher than among 16-20 year olds (p = 0.01).BMC Infectious Diseases 2009, 9:165 http://www.biomedcentral.com/1471-2334/9/165
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codes accounted for 83 of the 103 validated events. In
general, however, the positive predictive value of diagno-
sis codes for validated local reactions was low, with the
exceptions being the code for serum reaction, with a pos-
itive predictive value of 78%, and infection following vac-
cination, with a positive predictive value of 50%.
Validated illness possibly indicative of a hypersensitivity 
reaction
The estimated risk of a validated illness possibly indicative
of a hypersensitivity reaction, based on the 61 estimated
events, was 1.4 events per 10,000 vaccinations. Of the 26
events that were confirmed by chart review to have met
the study definition of an illness possibly indicative of a
hypersensitivity reaction, eight had hives or urticaria with-
out signs or symptoms involving other body systems,
seven had non-urticarial rashes without signs or symp-
toms involving other body systems, seven had a clinical
syndrome possibly consistent with an allergic reaction
with signs and symptoms other than rash, and four had
other clinical syndromes meeting the case definition. In
many cases the clinical syndrome was attributed to
another cause, such as exposure to an antibiotic or other
medication or a concomitant vaccination.
Of the seven illnesses possibly consistent with an allergic
reaction with signs and symptoms other than rash (with
or without rash), in most cases there was limited informa-
tion in the medical record and for all but one the available
documentation did not provide information to confirm
that the event met the Brighton Collaboration case defini-
tion of anaphylaxis. One case did meet that definition,
with Level 1 of diagnostic certainty, but this was a 15 year
old with known peanut allergy who had anaphylaxis after
eating peanuts the day after Td vaccination.
Discussion
In this study we found that validated medically attended
local reactions were uncommon following Td vaccina-
tion, with an overall estimated risk of 3.6 events per
10,000 Td vaccinations. The risk of medically-attended
local reactions varied by age, and was significantly higher
in the 9 to 10 and in the 21 to 25 year old age groups com-
pared with the risk in persons 11 to 20 years of age. In
addition, among the subgroup of persons with at least five
years of enrollment in the MCO prior to the Td vaccina-
tion, there was a statistically significant association
between receipt of a TDCV within five years prior to the Td
vaccination and a higher risk of a medically attended local
reaction to Td vaccine.
The elevated risk in the youngest age group is consistent
with the findings of Scheifele and colleagues, who
reported greater injection site morbidity following Td vac-
cination in 11 to 12 year olds compared with 14 to 16 year
olds [6]. This may have been due to the shorter interval
between completion of the DTaP vaccination series and
the Td vaccination in the younger age group. In our study,
it is also possible that differences in health care seeking
behavior among children and young adults contributed to
the observed differences in risk of local reactions resulting
in a medical visit. That is, if adolescents 11 through 15
years of age were less likely to seek medical care for a local
reaction than both younger and older persons this may
have contributed to the differences in risk of medically
attended local reactions observed.
Table 3: Risk of a validated medically attended local reaction following Td vaccination, by history of receipt of tetanus and diphtheria 
toxoid containing vaccinations1 in the prior five years, among persons with at least five years of enrollment in the MCO prior to the Td 
vaccination.
Age, years History of receipt of TDCV







Event risk (95% CI) 
per 10,000 Td 
vaccinations
Incidence rate ratio (95% 
confidence interval) 
comparing those with and 
without a history of a TDCV 
in the prior five years
9-10 Yes 1,161 2 17.2 (2.9, 53.2) 4.6 (0.6, 35.4)
No 8,015 3 3.7 (0.8, 17.2)
11-15 Yes 2,876 2 8.2 (2.1, 32.6) 3.0 (0.8, 11.4)
No 160,933 44 2.7 (1.8, 4.1)
16-20 Yes 1,962 1 5.9 (0.8, 42.5) 1.8 (0.2, 15.6)
No 27,713 9 3.3 (1.3, 8.2)
21-25 Yes 165 0 0 Not estimable
No 6,526 6 8.7 (3.1, 24.2)
All Yes 6,164 6 9.0 (3.7, 22.2) 2.9 (1.2, 7.2)
No 203,187 63 3.1 (2.2, 4.4)
CI = confidence interval
1 Includes Td vaccine as well as diphtheria, tetanus and pertussis vaccines administered as part of the childhood vaccination series.
2Based on multiple imputation; the total of the age-group specific estimates may not add up to the overall total due to rounding average values 
across imputed datasets.BMC Infectious Diseases 2009, 9:165 http://www.biomedcentral.com/1471-2334/9/165
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The Advisory Committee on Immunization Practices
(ACIP) has recommended a 10-year minimum interval for
routine administration of Td, although Td may be given
for prophylaxis of wounds that are neither clean nor
minor if there is no history of Td in the previous five years.
For adolescents, ACIP has recommended a minimum
interval of 5 years between the last pediatric DTaP and the
adolescent Td dose [7,8]. Accordingly, in the VSD popula-
tion, administration of Td within five years of a prior
TDCV was uncommon, and was reported in only 3% of
the subgroup of study subjects with at least five years of
MCO enrollment. Given the rarity of our outcome of
medically attended local reactions, we had a limited abil-
ity to identify an increased risk of these events among the
relatively small subgroup of persons who had received a
TDCV in the previous five years but our findings support
the minimum intervals for Td vaccination recommended
by ACIP. It should be noted, however, that those mini-
mum intervals do not apply to administration of Tdap
vaccine after Td vaccine. Data from clinical studies sup-
port the safety of administration of Tdap vaccine after Td
vaccine at intervals of less than five years [9] and current
recommendations indicate that Tdap may be given at
shorter intervals in order to provide protection against
pertussis [10,11].
Of the local reactions that were identified, for most the
area of local edema, erythema, or swelling was relatively
limited. Of the reactions noted to have local edema, ery-
thema, or swelling and with a reaction size noted, for 83%
the maximum diameter of edema, erythema or swelling
was reported as less than 10 cm. Three local reactions were
reported to involve the entire upper arm, and so may rep-
resent extensive limb swelling reactions, which have been
reported in children following the fourth and fifth doses
of DTaP vaccine [12-17], and which have been identified
from Vaccine Adverse Event Reporting System (VAERS)
reports in children and adults following Td, Tdap (unpub-
lished VAERS data), and many other vaccines [18].
Persons with a medically attended local reaction were fre-
quently given a clinical diagnosis of cellulitis and most of
those given a diagnosis of cellulitis were prescribed antibi-
otic treatment. In addition, 11% of persons not given a
diagnosis of cellulitis were also treated with antibiotics.
Overall, 28% of persons with a medically-attended local
reaction following Td vaccination were treated with anti-
biotics. This is similar to the proportion of children with
medically attended local reactions following the 4th or 5th
dose of DTaP who were prescribed antibiotics (21%) in a
prior postlicensure study of DTaP vaccine conducted in
the Group Health population [12]. Since infection is an
unlikely explanation for injection site inflammation
occurring within one or two days of Td vaccination,
increasing provider awareness of the potential for signifi-
cant injection site reactions following Td vaccine may
decrease the potentially inappropriate use of antibiotics
for those reactions. The Department of Defense Vaccine
Centers Healthcare Network website http://
www.vhc.info.org also provides algorithms for assess-
ment and treatment of vaccine local reactions that may
provide useful guidance for physicians who provide
immunization services or evaluate vaccine adverse events.
In contrast to local reactions, the signs and symptoms
occurring in persons meeting the definition of a validated
illness possibly indicative of a hypersensitivity reaction
could generally not be definitively attributed to vaccina-
tion. We also did not identify any case of anaphylaxis that
could be attributed to Td vaccine in this study. This is con-
sistent with a prior study in the VSD of children up to 17
years of age who were vaccinated during 1991 through
1997, which identified no cases of anaphylaxis following
152,636 Td vaccinations [19].
Two diphtheria toxoid containing vaccines, Tdap and
Menactra, were introduced in 2005 and are included in
the routine adolescent immunization schedule. Adoles-
cents who receive these vaccines may be exposed to
increased levels of diphtheria toxoid, which could be asso-
ciated with an increased risk of local reactions. While it is
possible that the safety profiles of Tdap and Menactra vac-
cines may differ from the safety profile of Td vaccine, the
results of this study suggest that medically attended local
reactions are likely to be uncommon following the more
recently introduced diphtheria toxoid containing vac-
cines. These findings provide a point of reference for
future evaluations of the safety profile of newer vaccines.
Conclusion
Medically attended local reactions were uncommon fol-
lowing Td vaccination. The risk of those reactions varied
by age and by prior receipt of TDCVs.
Competing interests
RB has received research grants Sanofi Pasteur, the manu-
facturer of Td vaccine distributed in the United States. LAJ
has received research grants from and served as a consult-
ant to Sanofi Pasteur. The other authors declare that they
have no competing interests.
Authors' contributions
LAJ conceived of the study and drafted the initial protocol.
All authors participated in the creation of the final proto-
col. LAJ, EAB, SJH, RB, AN, and CG provided oversite for
the data collection at their study site. OY and JN drafted
the study analysis plan and performed the study analyses.
LAJ drafted the manuscript and all authors read and
approved the final manuscript.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Infectious Diseases 2009, 9:165 http://www.biomedcentral.com/1471-2334/9/165
Page 7 of 7
(page number not for citation purposes)
Additional material
Acknowledgements
We thank the Vaccine Safety Datalink staff members for their important 
contributions to this study, including administrative and regulatory support, 
data management, programming, and medical record abstraction. We also 
acknowledge the support of the staff at America's Health Insurance Plans.
This study was funded through a subcontract with America's Health Insur-
ance Plans (AHIP) under contract 200-2002-00732 from the Centers for 
Disease Control and Prevention (CDC).
References
1. Wassilak SGF, Roper MR, Kretsinger K, Orenstein WA: Tetanus
toxoid.  In Vaccines 5 th edition. Edited by: Plotkin SA, Orenstein
WA, Offit PA. Philadelphia: Elsevier Inc; 2008:805-840. 
2. Chen RT, Glasser JW, Rhodes PH, Davis RL, Barlow WE, Thompson
RS, Mullooly JP, Black SB, Shinefield HR, Vadheim CM, et al.: Vaccine
Safety Datalink project: a new tool for improving vaccine
safety monitoring in the United States. The Vaccine Safety
Datalink Team.  Pediatrics 1997, 99(6):765-773.
3. DeStefano F: The Vaccine Safety Datalink project.  Pharmacoep-
idemiol Drug Saf 2001, 10(5):403-406.
4. Ruggeberg JU, Gold MS, Bayas JM, Blum MD, Bonhoeffer J, Friedlander
S, de Souza Brito G, Heininger U, Imoukhuede B, Khamesipour A, et
al.: Anaphylaxis: case definition and guidelines for data collec-
tion, analysis, and presentation of immunization safety data.
Vaccine 2007, 25(31):5675-5684.
5. Rubin DB, Schenker N: Multiple imputation in health-care data-
bases: an overview and some applications.  Stat Med 1991,
10(4):585-598.
6. Scheifele DW, Dobson S, Kallos A, Bjornson G, Ochnio JJ: Compar-
ative safety of tetanus-diphtheria toxoids booster immuniza-
tion in students in Grades 6 and 9.  Pediatr Infect Dis J 1998,
17(12):1121-1126.
7. Recommended childhood immunization schedule--United
States, 1995. Centers for Disease Control and Prevention.
MMWR Recomm Rep 1995, 44(RR-5):1-9.
8. Immunization of adolescents. Recommendations of the
Advisory Committee on Immunization Practices, the Amer-
ican Academy of Pediatrics, the American Academy of Fam-
ily Physicians, and the American Medical Association.
MMWR Recomm Rep 1996, 45(RR-13):1-16.
9. Halperin SA, Sweet L, Baxendale D, Neatby A, Rykers P, Smith B, Zel-
man M, Maus D, Lavigne P, Decker MD: How soon after a prior
tetanus-diphtheria vaccination can one give adult formula-
tion tetanus-diphtheria-acellular pertussis vaccine?  Pediatr
Infect Dis J 2006, 25(3):195-200.
10. Kretsinger K, Broder KR, Cortese MM, Joyce MP, Ortega-Sanchez I,
Lee GM, Tiwari T, Cohn AC, Slade BA, Iskander JK, et al.: Prevent-
ing tetanus, diphtheria, and pertussis among adults: use of
tetanus toxoid, reduced diphtheria toxoid and acellular per-
tussis vaccine recommendations of the Advisory Committee
on Immunization Practices (ACIP) and recommendation of
ACIP, supported by the Healthcare Infection Control Prac-
tices Advisory Committee (HICPAC), for use of Tdap
among health-care personnel.  MMWR Recomm Rep 2006,
55(RR-17):1-37.
11. Broder KR, Cortese MM, Iskander JK, Kretsinger K, Slade BA, Brown
KH, Mijalski CM, Tiwari T, Weston EJ, Cohn AC, et al.: Preventing
tetanus, diphtheria, and pertussis among adolescents: use of
tetanus toxoid, reduced diphtheria toxoid and acellular per-
tussis vaccines recommendations of the Advisory Commit-
tee on Immunization Practices (ACIP).  MMWR Recomm Rep
2006, 55(RR-3):1-34.
12. Jackson LA, Carste BA, Malais D, Froeschle J: Retrospective popu-
lation-based assessment of medically attended injection site
reactions, seizures, allergic responses and febrile episodes
after acellular pertussis vaccine combined with diphtheria
and tetanus toxoids.  Pediatr Infect Dis J 2002, 21(8):781-786.
13. Rennels MB, Deloria MA, Pichichero ME, Losonsky GA, Englund JA,
Meade BD, Anderson EL, Steinhoff MC, Edwards KM: Extensive
swelling after booster doses of acellular pertussis-tetanus-
diphtheria vaccines.  Pediatrics 2000, 105(1):e12.
14. Rennels MB, Black S, Woo EJ, Campbell S, Edwards KM: Safety of a
fifth dose of diphtheria and tetanus toxoid and acellular per-
tussis vaccine in children experiencing extensive, local reac-
tions to the fourth dose.  Pediatr Infect Dis J 2008, 27(5):464-465.
15. Sekaran NK, Edwards KM: Extensive swelling reaction associ-
ated with diphtheria and tetanus toxoids and acellular per-
tussis vaccine.  Pediatr Infect Dis J 2006, 25(4):374-375.
16. Scheifele DW, Halperin SA, Ferguson AC: Assessment of injection
site reactions to an acellular pertussis-based combination
vaccine, including novel use of skin tests with vaccine anti-
gens.  Vaccine 2001, 19(32):4720-4726.
17. Liese JG, Stojanov S, Zink TH, Froeschle J, Klepadlo R, Kronwitter A,
Harzer E, Jow S, Belohradsky BH: Safety and immunogenicity of
Biken acellular pertussis vaccine in combination with diph-
theria and tetanus toxoid as a fifth dose at four to six years
of age. Munich Vaccine Study Group.  Pediatr Infect Dis J 2001,
20(10):981-988.
18. Woo EJ, Burwen DR, Gatumu SN, Ball R: Extensive limb swelling
after immunization: reports to the Vaccine Adverse Event
Reporting System.  Clin Infect Dis 2003, 37(3):351-358.
19. Bohlke K, Davis RL, Marcy SM, Braun MM, DeStefano F, Black SB,
Mullooly JP, Thompson RS: Risk of anaphylaxis after vaccination
of children and adolescents.  Pediatrics 2003, 112(4):815-820.
Pre-publication history





Sensitivity and positive predictive value (PPV) of individual ICD9 
codes for identification of validated local reactions and validated 
events possibly indicative of a hypersensitivity response to Td vaccina-
tion. The data provided report the proportion of validated events that were 
associated with specific ICD9 codes.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2334-9-165-S1.DOC]